# US 2021/0275630 A1 · Inactivation of dna repair as an anticancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275630 A1
- Document ID: US20210275630A1
- Status: Published application
- Kind: A1
- Application number: 16/094,072
- Filed: 2017-04-18
- Published: 2021-09-09
- Earliest claimed: 2016-04-18
- Assignees: Phoremost Limited
- Applicants: Phoremost Limited
- Inventors: Alberto Bardelli; Giovanni GERMANO; Chris TORRANCE
- Web page: https://patentgrep.com/patent/US20210275630A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 38/1709: {from mammals}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 38/45: Transferases (2)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/82: Translation products from oncogenes
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12Q 1/00: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- C12Y 207/07007: DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

This invention relates to the modulation of DNA repair and nucleic acid editing mechanisms for use in the treatment of cancer. This invention relates to the inactivation of DNA repair and mechanisms for use in the treatment of cancer. This invention also relates to screening for new anti-cancer agents.

## Claims

### Claim 1

A method for treating cancer comprising:
a) providing i) a subject having cancerous cells, and ii) a modifier of a DNA repair or nucleic acid editing gene, or its protein product; and
b) treating said subject with said modifier wherein said treating reduces the number of cancerous cells in said subject.

### Claim 2 (depends on 1)

A method as claimed in claim 1 wherein the modifier of a DNA repair or nucleic acid editing gene or its protein product is an activator.

### Claim 3 (depends on 2)

A method as claimed in claim 2 wherein the DNA repair gene encodes a protein involved in translesion synthesis.

### Claim 4 (depends on 3)

A method as claimed in claim 3 wherein the DNA repair gene is DNA-pol η, ι or κ.

### Claim 5 (depends on 2)

A method as claimed in claim 2 wherein the nucleic acid editing gene encodes a protein involved in RNA or DNA editing.

### Claim 6 (depends on 5)

A method as claimed in claim 5 wherein the nucleic acid editing enzyme is ADAR1, ADAR2, ADAR3, ADARB2-AS1, AICDA, APOBEC3D, APOBEC3B, APOBEC3C, APOBEC3G, APOBEC3F, APOBEC3A, APOBEC3H, APOBEC1, A1CF, APOBEC2, APOBEC4, APOBEC3AP1 or APOBEC3B-AS1.

### Claim 7 (depends on 1)

A method as claimed in claim 1 wherein the modifier of a DNA repair or nucleic acid editing gene is an inactivator.

### Claim 8 (depends on 7)

A method as claimed in claim 7 wherein the DNA repair gene is an MMR gene.

### Claim 9 (depends on 8)

A method as claimed in claim 8 wherein the MMR gene is a MutL homologue.

### Claim 10 (depends on 9)

A method as claimed in claim 9 wherein the MutL homologue is MLH1, MutLα, MutLβ, MutLγ, PMS1, PMS2 or MLH3.

### Claim 11 (depends on 7)

A method as claimed in claim 7 wherein the nucleic acid editing enzyme is ADAR1, ADAR2, ADAR3, ADARB2-AS1, AICDA, APOBEC3D, APOBEC3B, APOBEC3C, APOBEC3G, APOBEC3F, APOBEC3A, APOBEC3H, APOBEC1, A1CF, APOBEC2, APOBEC4, APOBEC3AP1 or APOBEC3B-AS1.

### Claim 12 (depends on 1)

A method as claimed in claim 1, wherein the modifier is a polypeptide, polynucleotide, antibody, peptide or small molecule compound.

### Claim 13 (depends on 1)

A method as claimed in claim 1, wherein an inactivator is a molecule which provides inactivation through genome editing.

### Claim 14 (depends on 1)

A method as claimed in claim 1, wherein the cancer is an MMR +ve cancer.

### Claim 15 (depends on 1)

A method for treating cancer as claimed in claim 1, wherein the modifier of a DNA repair enzyme is provided in combination with a different cancer treatment.

### Claim 16 (depends on 15)

A method as claimed in claim 15 wherein the different cancer treatment is one which inactivates MMR genes.

### Claim 17 (depends on 16)

A method as claimed in claim 16 wherein the different cancer treatment is treatment with temozolomide or MNU or their derivatives.

### Claim 18 (depends on 15)

A method as claimed in claim 15 wherein the different cancer treatment is an immunotherapy.

### Claim 19 (depends on 18)

A method as claimed in claim 18 wherein the immunotherapy is an immune checkpoint inhibitor or combination of immune checkpoint inhibitors.

### Claim 20 (depends on 19)

A method as claimed in claim 19 wherein the immune checkpoint inhibitor is an anti-PD1 antibody, an anti-CTLA-4 antibody, an anti-PDL-1 antibody or combinations thereof.

### Claim 21 (depends on 1)

A method of treatment as claimed in claim 1 wherein the inactivator/inhibitor of a mismatch repair gene is temozolomide, MNU or their derivatives.

### Claim 22

A method for screening for anti-cancer compounds comprising
a) providing cells expressing a DNA repair or nucleic acid editing gene;
b) incubating said cells in the presence of a test compound; and
c) measuring the rate of DNA or RNA mutation in the presence of a test compound;
d) wherein an increased rate of DNA or RNA mutation in cells in the presence of a test compound compared to that measured in cells in the absence of a test compound indicates a test compound is an anti-cancer compound.

### Claim 23 (depends on 22)

A method as claimed in claim 22 wherein cells expressing a DNA repair gene are a human tumour cell line.

### Claim 24 (depends on 22)

A method as claimed in claim 22 wherein the DNA repair gene is MLH1, MutLα, MutLβ, MutLγ, PMS1, PMS2 or MLH3.

### Claim 25 (depends on 22, 23)

A method as claimed in claim 22 or claim 23 wherein the nucleic acid editing enzyme is ADAR1, ADAR2, ADAR3, ADARB2-AS1, AICDA, APOBEC3D, APOBEC3B, APOBEC3C, APOBEC3G, APOBEC3F, APOBEC3A, APOBEC3H, APOBEC1, A1CF, APOBEC2, APOBEC4, APOBEC3AP1 or APOBEC3B-AS1.

### Claim 26

A method of identifying a patient having a tumour suitable for treatment by immunotherapy comprising:
a) taking a sample of said tumour,
b) analysing said sample to determine the sequence of a DNA repair or nucleic acid editing gene, and
c) comparing the sequence of said DNA repair or nucleic acid editing gene in a tumour sample with the sequence in a non-tumour sample,
wherein a defect in the sequence of said DNA repair or nucleic acid editing gene in the tumour sample compared to the sequence of said gene in a non-tumour sample is indicative that said patient has a tumour suitable for treatment by immunotherapy.

### Claim 27

A method for screening for a modifier of a DNA repair or nucleic acid editing gene, or its protein product, comprising:
a) providing a construct wherein comprising a simple nucleotide sequence cloned upstream of a reporter coding sequence such that the reporter coding sequence is out of frame;
b) transfecting cells with the construct of a) in combination with a construct comprising a DNA repair or nucleic acid editing gene;
c) incubating said cells in the presence of a test compound; and
d) measuring a signal from the reporter construct;
e) wherein an increase in signal from the reporter construct in the presence of the test compound compared to the signal in the absence of the test compound indicates that the test compound is a modifier of said DNA repair or nucleic acid editing gene, or its protein product.

### Claim 28 (depends on 27)

A method as claimed in claim 27 wherein the simple nucleotide sequence is a CA dinucleotide repeat, preferably CA(20).

### Claim 29 (depends on 27)

A method as claimed in claim 27 wherein the DNA repair or nucleic acid editing gene in step b) is MLH1.

### Claim 30

An inactivator of MLH-1 comprising a CRISPR construct as described herein.
